Results 91 to 100 of about 38,007 (143)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. [PDF]

Neurology, 2019
Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, Goldberg JD, Li X, Riddle E, Smirnakis K, Kasliwal R, Ren Z, Hotermans C, Ho PR, Campbell N.   +14 more
europepmc   +1 more source

Extended Interval Dosing of Aminoglycosides in Renal Transplant Patients

Open Forum Infectious Diseases, 2015
Arnold Decano, Tiffany Bias, Alden Doyle, Gregory Malat   +3 more
openaire   +1 more source

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. [PDF]

Antimicrob Agents Chemother, 2018
Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR.   +4 more
europepmc   +1 more source

Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice. [PDF]

Antimicrob Agents Chemother, 2016
Lepak A, Marchillo K, VanHecker J, Azie N, Andes D.   +4 more
europepmc   +1 more source

Hereditary angioedema attack trends among patients maintained on lanadelumab long-term prophylaxis. [PDF]

J Allergy Clin Immunol Glob
O'Connor M, Jacobs J, Panattoni L, Gahlon G, Bariahtaris N, Sing K, Fox D, Schultz BG, Juethner S.   +8 more
europepmc   +1 more source

Opicapone Improves the Pharmacokinetics of Levodopa Administered as Extended-Release Capsules. [PDF]

Clin Neuropharmacol
LeWitt PA, Klepitskaya O, Olson K, Liang G, Loewen G.   +4 more
europepmc   +1 more source

A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shock. [PDF]

J Antimicrob Chemother
Sulaiman H, Wölky SA, Rozali MA, Adiraju SKS, Hasan MS, Hernandez-Mitre MP, Liu X, Mat-Nor MB, Mazlan MZ, Salmuna ZN, Wallis SC, Xie J, Roberts JA, Abdul-Aziz MH.   +13 more
europepmc   +1 more source

Lanadelumab in Hereditary Angioedema: Extending Dose Intervals from Every 2 Weeks to Every 4 Weeks.

Int Arch Allergy Immunol
Riedl MA, Soteres D, Davis-Lorton MA, Piccolo T, Otule M, Andresen I, Craig T.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Efficacy and safety of natalizumab extended interval dosing

Multiple Sclerosis and Related Disorders, 2018
It is postulated that extending the dosing interval of natalizumab (NTZ) from 4 to 5-8 weeks might decrease the risk of progressive multifocal leukoencephalopathy (PML). The aim of this study was to assess the effect of extended interval dosing (EID) on the therapeutic efficacy of natalizumab.We reviewed 85 patients treated at two MS centers in the ...
Hani Tamim, Bassem Yamout, Mohammad Ali Sahraian   +2 more
exaly   +3 more sources